Eton Pharmaceutical ETON 深 沪
等待开盘 09-18 09:30:00 美东时间
17.68
+0.120
+0.68%
华盛通- 最 高18.00
- 今 开17.64
- 成交量 14.78万股
- 最 低 17.48
- 昨 收 17.56
- 总市值 4.74亿
- 52周最高 21.48
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 5.72
- 委 比 29.20%
- 总股本 2681.75万
- 历史最高 21.48
- 量 比 0.67
- 振 幅 2.96%
- 历史最低 1.95
- 每 手 1
- 风险率 3.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CytoSorbents Provides DrugSorb-ATR Regulatory Update
PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surge...
09-16 19:00
Miami International Holdings Launches Next-Generation Options Trading Floor in Miami
MIAMI and PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ -- Miami International Holdings, Inc. (MIAX®) (NYSE: MIAX), a technology-driven leader in building and operating regulated financial ma...
09-16 18:45
BioNTech, Bristol Myers Squibb Present Interim Data From Global Randomized Phase 2 Trial Evaluating Pumitamig, Investigational Bispecific Antibody Targeting PD-L1 X VEGF-A, Plus Chemotherapy In ES-SCLC Patients
PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer ("ES-SCLC"), expanding evidence for
09-08 23:03
Miami International Holdings Reports Trading Results for August 2025
PRINCETON, N.J. and MIAMI, Sept. 8, 2025 /PRNewswire/ -- Miami International Holdings, Inc. (NYSE: MIAX) (MIAX), a technology-driven leader in building and operating regulated financial mark...
09-08 21:15
CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference
PRINCETON, N.J., Sept. 5, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surger...
09-05 19:00
PDS Biotechnology Reports Median Overall Survival Of 39.3 Months In HPV16-Positive Head And Neck Cancer Patients
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months*VERSATILE-003 Phase 3 trial in
08-25 20:34
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR
FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization PRINCETON, N.J., Aug. 20, 20...
08-20 19:00
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
DETON Pharmaceuticals announced that its executive team will hold 1x1 meetings at the 2025 Wells Fargo Healthcare Conference in Boston. The company focuses on developing treatments for rare diseases and currently has eight commercial products. Additional details can be found on their website.投资者如需安排会议，请联系Wells Fargo的机构销售代表。
08-20 10:50
Palatin Announces 1-for-50 Reverse Stock Split
PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its shares at a ratio of 1-for-50. Th...
08-09 04:00
Eton Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results.
Eton Pharmaceuticals shares are trading higher after the company reported bette...
08-08 05:06
